PMA device
Evolut FX+ TAV, Evolut FX DCS, Evolut FX LS
Medtronic, Inc. · Aortic Valve, Prosthesis, Percutaneously Delivered (NPT, Class III) · First FDA decision Mar 22, 2024, newest Mar 22, 2024Aortic stenosis
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
PMA pathway
Device trials
1
Naming "Evolut FX+ TAV"
MAUDE reports
0
Brand "Evolut FX+ TAV", since 2015
PubMed studies
0
Mentioning "Evolut FX+ TAV"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Evolut FX+ TAV, Evolut FX DCS, Evolut FX LS
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- Evolut FX+ TAV, Evolut FX DCS, Evolut FX LSPMA supplement
P130021-S155 · Decided Mar 22, 2024 · 56 days after receipt · Normal 180 Day Track
Device type: Aortic valve, prosthesis, percutaneously delivered (NPT) · Cardiology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Transcatheter Aortic Valve Replacement (TAVR)National analysisReview closedCAG-00430RUpdated Sep 23, 2026
- Transcatheter Aortic Valve Replacement (TAVR)National analysisReview closedCAG-00430NUpdated Sep 23, 2026
- Transcatheter Aortic Valve Replacement (TAVR) for Aortic Regurgitation (AR)National analysisUnder reviewCAG-00430R3Updated Sep 14, 2026
- Transcatheter Aortic Valve Replacement (TAVR)National analysisReview closedCAG-00430R2Updated Sep 10, 2026
- Transcatheter Aortic Valve Replacement (TAVR)National determinationOn the books20.32Updated Aug 16, 2023
Clinical trials
Device studies on ClinicalTrials.gov that name "Evolut FX+ TAV", any status and sponsor, newest update first.
- SMall Annuli Randomized To Evolut™ or SAPIEN™ TrialPivotal-lookingActive, not recruiting
Medtronic CardiovascularPublic (MDT)
NCT04722250 · 1,103 participants · Start Apr 2, 2021 · Primary completion Nov 10, 2023
Device: Medtronic Evolut PRO, Evolut PRO+ or Evolut FX (where commercially available) TAV Systems; Edwards SAPIEN 3 or SAPIEN 3 Ultra THV Systems · For: Symptomatic Aortic Stenosis; Aortic Valve Stenosis; Aortic Valve Replacement
Sites: La Jolla, California; Los Angeles, California; San Francisco, California · 92 sites in all
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Evolut FX+ TAV", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code NPT
77,669 reports: 12,243 malfunction, 57,723 injury, 7,693 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Medtronic Heart Valves Division
Z-0559-2021 · Started Oct 23, 2020
Reason given: Potential for Transcatheter Aortic Valve (TAV) leaflet damage when performing a post-implant balloon dilatation (PID).
Cause as FDA categorized it: Labeling design · Device type: Aortic Valve, Prosthesis, Percutaneously Delivered (NPT)
Medtronic Heart Valves Division
Z-0560-2021 · Started Oct 23, 2020
Reason given: Potential for Transcatheter Aortic Valve (TAV) leaflet damage when performing a post-implant balloon dilatation (PID).
Cause as FDA categorized it: Labeling design · Device type: Aortic Valve, Prosthesis, Percutaneously Delivered (NPT)
Medtronic Heart Valves Division
Z-0561-2021 · Started Oct 23, 2020
Reason given: Potential for Transcatheter Aortic Valve (TAV) leaflet damage when performing a post-implant balloon dilatation (PID).
Cause as FDA categorized it: Labeling design · Device type: Aortic Valve, Prosthesis, Percutaneously Delivered (NPT)
1 more recall records with a free account
Published research
The most relevant PubMed records for "Evolut FX+ TAV"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code NPT.
- Sapien 3 Transcatheter Heart Valve and AccessoriesEdwards Lifesciences, LLC · PMA 2025
- Medtronic CoreValve Evolut R SystemMedtronic, Inc. · PMA 2022
- Edwards SAPIEN XT Transcatheter Heart ValveEdwards Lifesciences, LLC · PMA 2020
- Edwards SAPIEN 3 Ultra RESILIA Transcatheter Heart ValveEdwards Lifesciences, LLC · PMA 2026
- Medtronic CoreValve SystemMedtronic, Inc. · PMA 2023
- Edwards Sapien Transcatheter Heart Valve and Transfemoral and Transapical AccessoriesEdwards Lifesciences, LLC · PMA 2013
- Navitor Transcatheter Aortic Valve Implantation SystemAbbott Medical · PMA 2026
- Trilogy Transcatheter Heart Valve SystemJenaValve Technology, Inc. · PMA 2026
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.